Author

J. A. Boland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:bacteria (other)· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

A. G. Coyne· 1 shared C. Abell· 1 shared C. Spry· 1 shared G. W. McCaughan· 1 shared J. C. Evans· 1 shared J. Chen· 1 shared J. El Bakali· 1 shared K. Luo· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. G. Coyne

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transplantation of high fat fed mouse microbiota into zebrafish larvae identifies MyD88-dependent acceleration of hyperlipidaemia by Gram positive cell wall components

P. M. Cholan, S. Morris, K. Luo, J. Chen, J. A. Boland, G. W. McCaughan, W. J. Britton, S. H. Oehlers

The paper transplants mouse high fat diet microbiota into zebrafish larvae to identify microbial factors that accelerate hyperlipidaemia via MyD88 signaling.

bioRxiv · Apr 28, 2021 · PreprintMicrobiology

Chemical validation of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase using fragment linking and CRISPR interference

J. El Bakali, M. Blaszczyk, J. C. Evans, J. A. Boland, W. J. McCarthy, M. V. B. Dias, A. G. Coyne, V. Mizrahi, T. L. Blundell, C. Abell, C. Spry

This study identifies inhibitors of MtbPPAT, a key enzyme in CoA biosynthesis, using fragment linking and CRISPR interference to validate it as a potential anti-TB drug target.

bioRxiv · Sep 4, 2020Biochemistry